Good FDA news, price is consolidating. Does this break out?
FULC a biotechnology firm with a mixed earnings report early in the month just printed a big move and then stalled at the NY lunch - hour and faded. Will the fade continue or will there be an upward continuation? The 15 -minute chart seems to suggest a downtrend: 1, The volume profile shows heavy trading at the top. This could be short sellers...
FULC on the 15 minute chart had a good response to favorable earnings and then retraced. It is now bounding off the Fib 0.5 level and also confluent with the POC line of the volume profile and the mean of the anchored VWAP. Buying volume appropriately overtook selling volume on the reversal Luxalgo's Echo indicator, an AI predictive tool, suggests a 10%...
$FULC - Consolidating in tight range while surfing 10 DMA - Tightening up after strong run up - Strong momentum runner: +150% in 1 month
Pupm&Dump trading strategy idea. $FULC is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $20,49; stop-loss — $21,32; take-profit — $18,82/MOC Do not view this idea as a recommendation for trading or investing. It is...
FULC: Fulcrum Therapeutics, Inc. 2021-08-10 07:00:00 Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease
FULC news catalyst popped the stock into the previous gap and right back to testing this clear resistance level that was previous support. After plotting the fib retracement is looks like the 50 Fib line is an area that might need to set up as the higher support level if there's any hope of FULC sustaining higher levels. We'll have to see what happens next. "The...
I like the chart here but it will depend on a catalyst to drive it higher. A nice place to start accumulating shares.
First of All , shout out to Horizontal Price Levels Trading (on tradingview), I originally read their publication on FULC which was what spurred my original interest. Secondly, Bio-tech is NOT my strong point , as I do not have a medical background and reading the news reports these kinds of stocks produce can be hard for me to comprehend Example from Quoted...
Entry level $15.96 = Target price $20.63 Alert set for breakout above $15.61 Average analysts price target $12 | Buy rating Earnings call transcript We believe our approach to the treatment of genetically defined diseases using a small molecule approach may offer significant advantages over other treatment modalities since small molecules can achieve broad...